Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Autologous HERV-E TCR transduced T cells |
| Synonyms | |
| Therapy Description |
Autologous HERV-E TCR transduced T cells are patient-derived T-cells engineered to express a T-cell receptor (TCR) targeting an HLA-A-A11-restricted HERV-E peptide, which potentially induce antitumor activity (PMID: 39266213). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Autologous HERV-E TCR transduced T cells | Autologous CT-RCC-1 HERV-E-TCR-transduced-HLA-A11-restricted CD8+/CD34t+ T-cells | Autologous HERV-E TCR transduced T cells are patient-derived T-cells engineered to express a T-cell receptor (TCR) targeting an HLA-A-A11-restricted HERV-E peptide, which potentially induce antitumor activity (PMID: 39266213). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03354390 | Phase I | Autologous HERV-E TCR transduced T cells | HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma | Active, not recruiting | USA | 0 |